MedTrace Logo

Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma

NCT00443924 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2015-01-21

No results posted yet for this study

Summary

The purpose of this trial is to evaluate the safety and tolerability of INS115644 Ophthalmic Solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma and to investigate the intraocular pressure lowering effects of INS115644 Ophthalmic Solution.

Conditions

Interventions

DRUG

INS115644 Ophthalmic Solution

One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days

DRUG

Placebo

One drop of placebo in each eye every 12 hours for three days

DRUG

INS115644 Ophthalmic Solution

One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days

DRUG

INS115644 Ophthalmic Solution

One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days

DRUG

INS115644 Ophthalmic Solution

One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-04-30
Completion
2009-04-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00443924 on ClinicalTrials.gov